Terms: = Colorectal cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
1069 results:
1. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of colorectal cancer in Tibet].
Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
[TBL] [Abstract] [Full Text] [Related]
2. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract] [Full Text] [Related]
3. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
4. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and pd-l1.
Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
[TBL] [Abstract] [Full Text] [Related]
5. Arenobufagin enhances T-cell anti-tumor immunity in colorectal cancer by modulating HSP90β accessibility.
Shang Z; Fan Y; Xi S; Zhang S; Shen W; Tao L; Xu C; Tan J; Fan M; Ma H; Lai Y; Sun D; Cheng H
Phytomedicine; 2024 Jun; 128():155497. PubMed ID: 38640855
[TBL] [Abstract] [Full Text] [Related]
6. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and pd-l1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract] [Full Text] [Related]
7. The Tumor Microenvironment Mediates the HIF-1α/pd-l1 Pathway to Promote Immune Escape in colorectal cancer.
Sun J; Zhao Z; Lu J; An W; Zhang Y; Li W; Yang L
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612546
[TBL] [Abstract] [Full Text] [Related]
8. GSK0660 enhances antitumor immunotherapy by reducing pd-l1 expression.
Khan B; Chen M; Wang H; Khan A; Hussain S; Shi J; Yang L; Hou Y
Eur J Pharmacol; 2024 Jun; 972():176565. PubMed ID: 38599309
[TBL] [Abstract] [Full Text] [Related]
9. [Expression of immune checkpoints pd-l1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
[TBL] [Abstract] [Full Text] [Related]
10. Case report: Envafolimab causes local skin necrosis.
Liu JJ; Xu XY; Han H; Wang T; Zhang W; Cui J; Semenov M
Front Immunol; 2024; 15():1336311. PubMed ID: 38585260
[TBL] [Abstract] [Full Text] [Related]
11. Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer.
Zhou Y; Li H; Zhang Y; Zhao E; Huang C; Pan X; Shu F; Liu Z; Tang N; Li F; Liao W
Cancer Lett; 2024 May; 589():216836. PubMed ID: 38556105
[TBL] [Abstract] [Full Text] [Related]
12. Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients.
Luo S; Liu Z; Chang H; Cheng X; Qian R; Gao Y; Hou C
Aging (Albany NY); 2024 Mar; 16(7):6188-6211. PubMed ID: 38552216
[TBL] [Abstract] [Full Text] [Related]
13. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
[TBL] [Abstract] [Full Text] [Related]
14. Associations of PD-1 and pd-l1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
15. Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic colorectal cancer.
Gherman A; Bolundut D; Ecea R; Balacescu L; Curcean S; Dina C; Balacescu O; Cainap C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541123
[TBL] [Abstract] [Full Text] [Related]
16. Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.
Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
[TBL] [Abstract] [Full Text] [Related]
17. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
[TBL] [Abstract] [Full Text] [Related]
18. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A; Morel D; Texier M; Sun R; Durand-Labrunie J; Rodriguez-Ruiz ME; Racadot S; Supiot S; Magné N; Cyrille S; Louvel G; Massard C; Verlingue L; Bouquet F; Bustillos A; Bouarroudj L; Quevrin C; Clémenson C; Mondini M; Meziani L; Tselikas L; Bahleda R; Hollebecque A; Deutsch E
Mol Cancer; 2024 Mar; 23(1):61. PubMed ID: 38519913
[TBL] [Abstract] [Full Text] [Related]
19. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
Cartwright E; Slater S; Saffery C; Tran A; Turkes F; Smith G; Aresu M; Kohoutova D; Terlizzo M; Zhitkov O; Rana I; Johnston EW; Sanna I; Smyth E; Mansoor W; Fribbens C; Rao S; Chau I; Starling N; Cunningham D
ESMO Open; 2024 Apr; 9(4):102971. PubMed ID: 38518549
[TBL] [Abstract] [Full Text] [Related]
20. Co-inhibition of TGF-β and pd-l1 pathways in a metastatic colorectal cancer mouse model triggers interferon responses, innate cells and T cells, alongside metabolic changes and tumor resistance.
Nair R; Lannagan TRM; Jackstadt R; Andrusaite A; Cole J; Boyne C; Nibbs RJB; Sansom OJ; Milling S
Oncoimmunology; 2024; 13(1):2330194. PubMed ID: 38516270
[TBL] [Abstract] [Full Text] [Related]
[Next]
